UBS Group’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-64,920
| Closed | -$262K | – | 10307 |
|
|
2025
Q1 | $262K | Sell |
64,920
-6,846
| -10% | -$22.8K | ﹤0.01% | 6352 |
|
|
2024
Q4 | $230K | Buy |
71,766
+66,488
| +1,260% | +$225K | ﹤0.01% | 6371 |
|
|
2024
Q3 | $11.8K | Buy |
5,278
+3,777
| +252% | +$8.72K | ﹤0.01% | 7662 |
|
|
2024
Q2 | $3.23K | Hold |
1,501
| – | – | ﹤0.01% | 8242 |
|
|
2024
Q1 | $3.08K | Sell |
1,501
-23
| -2% | -$46 | ﹤0.01% | 7773 |
|
|
2023
Q4 | $3.49K | Sell |
1,524
-88
| -5% | -$192 | ﹤0.01% | 7961 |
|
|
2023
Q3 | $2.74K | Sell |
1,612
-1,140
| -41% | -$2.59K | ﹤0.01% | 7655 |
|
|
2023
Q2 | $6.8K | Buy |
2,752
+1,252
| +83% | +$3.42K | ﹤0.01% | 7335 |
|
|
2023
Q1 | $3.38K | Sell |
1,500
-2,303
| -61% | -$11.6K | ﹤0.01% | 8329 |
|
|
2022
Q4 | $19.4K | Buy |
3,803
+731
| +24% | +$5.27K | ﹤0.01% | 7675 |
|
|
2022
Q3 | $32K | Buy |
3,072
+903
| +42% | +$10.8K | ﹤0.01% | 6788 |
|
|
2022
Q2 | $22K | Buy |
2,169
+319
| +17% | +$4.18K | ﹤0.01% | 6746 |
|
|
2022
Q1 | $33K | Sell |
1,850
-630
| -25% | -$13.5K | ﹤0.01% | 6902 |
|
|
2021
Q4 | $77K | Sell |
2,480
-1,129
| -31% | -$37.4K | ﹤0.01% | 6524 |
|
|
2021
Q3 | $119K | Buy |
3,609
+234
| +7% | +$6.92K | ﹤0.01% | 5700 |
|
|
2021
Q2 | $100K | Sell |
3,375
-1,458
| -30% | -$40.4K | ﹤0.01% | 5876 |
|
|
2021
Q1 | $152K | Buy |
4,833
+3,813
| +374% | +$128K | ﹤0.01% | 5651 |
|
|
2020
Q4 | $27K | Buy |
1,020
+993
| +3,678% | +$25.1K | ﹤0.01% | 6718 |
|
|
2020
Q3 | $1K | Sell |
27
-1,690
| -98% | -$40.6K | ﹤0.01% | 7765 |
|
|
2020
Q2 | $34K | Sell |
1,717
-1,461
| -46% | -$26.6K | ﹤0.01% | 6183 |
|
|
2020
Q1 | $48K | Buy |
3,178
+137
| +5% | +$2.42K | ﹤0.01% | 5858 |
|
|
2019
Q4 | $52K | Buy |
3,041
+1,154
| +61% | +$19.3K | ﹤0.01% | 6330 |
|
|
2019
Q3 | $47K | Buy |
1,887
+1,471
| +354% | +$40.4K | ﹤0.01% | 6234 |
|
|
2019
Q2 | $13K | Buy |
416
+332
| +395% | +$13K | ﹤0.01% | 6886 |
|
|
2019
Q1 | $2K | Buy |
+84
| New | +$2.68K | ﹤0.01% | 7422 |
|
|
2018
Q2 | – | Sell |
-32
| Closed | -$1K | – | 8001 |
|
|
2018
Q1 | $1K | Sell |
32
-52
| -62% | -$2.26K | ﹤0.01% | 7627 |
|
|
2017
Q4 | $3K | Buy |
84
+3
| +4% | +$157 | ﹤0.01% | 7524 |
|
|
2017
Q3 | $7K | Sell |
81
-59
| -42% | -$5.13K | ﹤0.01% | 7057 |
|
|
2017
Q2 | $14K | Buy |
+140
| New | +$13.8K | ﹤0.01% | 6534 |
|
UBS Group's CKPT Position: Q2 2025 in Review
UBS Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 64,920 shares — an estimated $262K sold.
UBS Group first reported a position in CKPT in Q2 2017 and held it in 29 quarters. The position peaked at $262K in Q1 2025. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- UBS Group reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- UBS Group sold 64,920 Checkpoint Therapeutics shares in Q2 2025, an estimated $262K.
- UBS Group first reported a position in Checkpoint Therapeutics in Q2 2017 and held it in 29 quarters.
- UBS Group's Checkpoint Therapeutics position peaked at $262K in Q1 2025.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.